Ann: CEO and Managing Director increases shareholding in Imugene, page-133

Vivo. Suggest you do just a small bit of research before making a fool of yourself.

This was published not so long ago:

"RESULTS FROM PHASE1B CLINICAL STUDY
In an earlier phase Ib study which examined 14 patients (14 sites across 5 countries) with HER-2 positive gastric cancer patients (open label, single arm, dose escalating study) the three patients on the optimal dose (50µg) plus chemotherapy progressed at 266, 355 and 424 days after starting treatment with IMU-131, with a mean progression free survival period of 355 days. There were no safety related issues associated with IMU-131. Tumour response measured according to RECIST1.1.These patients also showed the highest and most consistent levels of p467 specific antibodies and HER-2 specific antibodies compared to patients on lower doses with the preliminary response data also showing reduction in target tumour size."

Will let you go find the standard of care comparison survival for grade IV patients... or can spoon feed you, approx 100 days.

That won't change, what will is the number of patients being measured. Not long to go I'm told.